These observations and the findings outlined here prospectively render a combined application of PI3K and multi kinase inhibitors as a promising therapeutic option targeting Rac1 as a key downstream effector governed by both signalling pathways in medulloblastoma. This evidence concerns the gene RAC1 and medulloblastoma.